SINGAPORE, September 23, 2022 /PRNewswire/ — Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced the official opening of its office and research at the Singapore Science Park. Deputy Prime Minister and Coordinating Minister of Economic Policies Heng Sweet Keat officiated the opening ceremony of the Galen on 23rd September 2022. Located in The Galen and The Aries buildings, Hummingbird Bioscience’s 40,000 square foot space houses more than 10 state-of-the-art labs integrated with offices.
“This is an important milestone for the Hummingbird Bioscience team, which has come a long way since the company was founded in 2015,” said Piers Ingram, Ph.D., CEO and co-founder of Hummingbird Bioscience. “The Hummingbird Bioscience team has grown to a current headcount of 150 people responsible for the full range of drug discovery and development activities, from target validation, antibody discovery, bioinformatics to development clinical. We look forward to welcoming more talented teammates to our new location.
Company Singapore (EnterpriseSG) has closely supported Hummingbird Bioscience in its growth, including the development of its technology platform. SEEDS Capital, the investment arm of EnterpriseSG, also co-invested in the company. Said Soh Long WanDeputy General Manager (Manufacturing and Engineering) of EnterpriseSG, “The Singapore The biotech innovation scene has grown rapidly since our early investments in biomedical research. Today, there are more than 40 therapeutic biotechnologies in Singapore with many achieving good traction. In 2021, Singapore-based biotechs collectively raised more than 860 million Singapore dollars. Hummingbird Bioscience is an example of a biotechnology company that has successfully raised funds and continues to build capacity to develop its clinical-stage assets. This will generate new job opportunities in biotechnology in Singapore.”
Strengthen internal capacities
The pharmacology, mass spectrometry, analytical science, manufacturing, genomics, discovery, engineering and microbiology laboratories will allow the Hummingbird Bioscience team to accelerate their research in biotherapy. Integrated into the office space, the proximity allows a collaborative environment in several disciplines.
“We will continue to build an interdisciplinary team motivated to solve complex scientific problems with creative solutions. Our integrated approach aims to accelerate the drug discovery and development process while reducing the inherent risks,” said Jerome Boyd-KirkupPh.D., Scientific Director and Co-Founder of Hummingbird Bioscience.
Precision Oncology Symposium | X Marks The Spot: Treating Cancer With Precision
Prior to the opening ceremony, Hummingbird Bioscience hosted a precision oncology symposium titled “X Marks the Spot: Treating Cancer with Precision.” Renowned scientists and oncologists shared their experiences in precision oncology and discussed recent key themes during a panel discussion.
- dr. Thomas J. Lynch Jr.president and director of the Fred Hutchinson Cancer Center
- Teacher. Chng Wee Joo, Director and Senior Consultant, National University cancer institute, Singapore, National University Health system
- dr. Eric RowinskyChief Medical Officer, Hummingbird Bioscience
- dr. Jerome Boyd-KirkupScientific Director, Hummingbird Bioscience
- dr. Piers IngramPresident and CEO, Hummingbird Bioscience
About Hummingbird Bioscience
Hummingbird Bioscience is a data-driven, precision biotherapeutics company discovering and developing transformative biological medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multidisciplinary collaborative environment spanning initial discovery through clinical development. We leverage this integrated approach through target identification and patient selection, enabling our team to increase the efficiency of translation of new scientific knowledge while reducing the risk inherent in drug discovery and development. We are currently developing two clinical-stage actives: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in phase 1 studies. At Hummingbird Bioscience, our commitment to rigorous science, teamwork and intellectual integrity underpins our passion for accelerating the journey of new drugs from concept to clinic.
For more information, visit www.hummingbirdbioscience.com and follow Hummingbird Bioscience on LinkedIn, Twitterand YouTube.
SOURCE Colibri Bioscience